Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (From MESA)

Low-dose rivaroxaban was effective in secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in the COMPASS trial. There is no established role, however, for oral anticoagulants in primary prevention. We evaluated whether coronary artery calcium (CAC) scoring identifies a high-risk p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cardiol
Autori principali: Arps, Kelly, Rifai, Mahmoud Al, Blaha, Michael J., Michos, Erin D., Nasir, Khurram, Yeboah, Joseph, Budoff, Matthew J., Blumenthal, Roger S., Bittencourt, Marcio S., McEvoy, John W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6755041/
https://ncbi.nlm.nih.gov/pubmed/31416591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjcard.2019.07.016
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi